Search

Search Constraints

You searched for: Author/Creator Field, J.K.

Search Results

2. 58O Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): Interim analysis from the PACIFIC-R study. (December 2022)